Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production

Atherosclerosis

Volumn 191, Issue 2, 2007, Pages 250-258

  Jeng, Jiiang Huei ^a   Wu, Hui Lin ^a   Lin, Bor Ru ^a   Lan, Wan Hong ^a   Chang, Hsiao Hwa ^a   Ho, Yuan Soon ^b   Lee, Po Hsuen ^c   Wang, Ying Jan ^d   Wang, Juo Song ^a   Chen, Yi Jane ^a   Chang, Mei Chi ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Antiplatelet; Bleeding time; Calcium; cAMP; Cyclooxygenase; Platelet aggregation; Sanguinarine; Thromboxane

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; ARACHIDONIC ACID; CALCIUM ION; COLLAGEN; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; SANGUINARINE; THROMBIN; THROMBOXANE; THROMBOXANE B2; THROMBOXANE RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ARTICLE; CALCIUM MOBILIZATION; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FATTY ACID SYNTHESIS; IC 50; INHIBITION KINETICS; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADENYLATE CYCLASE; ALKALOIDS; ANIMALS; ARACHIDONIC ACID; BENZOPHENANTHRIDINES; BLOOD PLATELETS; CALCIUM; COLLAGEN; CYCLIC AMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ISOQUINOLINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; RECEPTORS, THROMBOXANE; THROMBIN; THROMBOXANE B2;

EID: 33947198685     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.05.023     Document Type: Article

References (46)

1. Shamma M., and Guinaudeau H. Apophinoid alkaloids. Nat Prod Rep 3 (1986) 345-351
2. Walterova D., Ulrichova J., Valka I., et al. Benzo[c]phenanthridine alkaloids sanguinarine and chelerythrine: biological activities and dental care applications. Acta Univ Palacki Olomuc Fac Med 139 (1995) 7-16
3. Lenfeld J., Kroutil M., Marsalek E., et al. Anti-inflammatory activity of quaternary benzo- phenanthridine alkaloids from Chelidonium majus. Planta Med 43 (1981) 161-165
4. Agarwal S., Reynolds M.A., Pou S., et al. The effect of sanguinarine on human peripheral blood neutrophil viability and functions. Oral Microbiol Immunol 6 (1991) 51-61
5. +-ATPase. Eur J Pharmacol 60 (1979) 373-377
6. Cohen H.G., Seifen E.E., Straub K.D., Teifenback C., and Stermitz F.R. Structural specificity of the NaK-ATPase inhibition by sanguinarine, an isoquinoline benzophenanthridien alkaloid. Biochem Pharmacol 27 (1978) 2555-2558
7. Tanaka S., Sakata Y., Morimoto K., et al. Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules ICAM-1 and VCAM-1. Planta Med 67 (2001) 108-113
8. Chaturvedi M.M., Kumar A., Darnay B.G., et al. Sanguinarine (pseudo chelerythrine) is a potent inhibitor of NF-kB activation, Ikα phosphorylation, and degradation. J Biol Chem 272 (1997) 30129-30134
9. Vogt A., Tamewitz A., Skoko J., et al. The benzo(c)phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogen-activated protein kinase phosphatase-1. J Biol Chem 280 (2005) 19078-19086
10. Parsons L.G., Thorns L.G., Southard G.L., Woodall I.R., and Jones B.J.B. Effect of sanguinaria extract on established plaque and gingivitis when supragingivally delivered as a manual rinse or under pressure in an oral irrigator. J Clin Periodontol 14 (1987) 381-385
11. Laster L.L., and Lobene R.P. New perspectives on sanguinarine clinicals: individual toothpaste and oral rinse testing. J Can Dent Assoc 56 Suppl. (1990) 19-23
12. Godowski K.C., Wolff E.D., Thompson D.M., et al. Whole mouth microbiota effects following subgingival delivery of sanguinarum. J Periodontol 66 (1995) 870-877
13. Francos V.H., Brusick D.J., Johnson E.M., et al. Safety of sauguinaria extract as used in commercial toothpaste and oral rinse products. J Can Dent Assoc 56 Suppl. (1990) 41-47
14. Maseri A. Inflammation in acute coronary syndrome. Haematologica 86 (2001) 1-2
15. Willoughby S., Holmes A., and Losalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 1 (2002) 273-288
16. Huang E.M., and Detwiler T.C. Stimulus-response coupling mechanisms. In: Phillips D.R., and Shuman M.A. (Eds). Biochemistry of platelets (1986), Academic Press, New York 1-50
17. Gupta G.P., and Massague J. Platelets and metastasis revisited: a novel fatty link. J Clin Invest 114 (2004) 1691-1693
18. Scheinitz M.D., and Heidenreich P.A. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med 142 (2005) 251-259
19. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 96 (2005) 612-616
20. Jeng J.H., Chen S.Y., Liao C.H., et al. Modulation of platelet aggregation by areca nut and betel leaf ingredients: roles of reactive oxygen species and cyclooxygenase. Free Rad Biol Med 32 (2002) 619-630
21. Lei D., Chan C.P., Wang Y.J., et al. Antioxidant and antiplatelet effect of inflorescence piper betle ingredients. J Agric Food Chem 51 (2003) 2083-2088
22. Chan C.P., Ho Y.S., Wang Y.J., et al. Inhibition of cyclooxygenase activity, platelet aggregation and thromboxane B2 production by two environmental toxicants: m-cresol and o-cresol. Toxicology 208 (2005) 95-104
23. Born G.V.R., and Cross M.J. The aggregation of blood platelets. J Physiol 168 (1963) 178-195
24. Teng C.M., and Ko F.N. Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. Thromb Haemost 59 (1988) 304-309
25. Huang T.F., Chang M.C., and Teng C.M. Antiplatelet protease, kistomin, selectively cleaves human platelet glycoprotein Ib. Biochim Biophys Acta 1158 (1993) 293-299
26. Rosado J.A., and Sage S.O. The ERK cascade, a new pathway involved in the activation of store-mediated calcium entry in human platelets. Trends Cardiovasc Med 12 (2002) 229-234
27. Feijge M.A., Ansink K., Canschoonbeek K., and Heemskerk J.W. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Biochem Pharmacol 67 (2004) 1559-1567
28. Tran H., and Anand S.S. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. J Am Med Assoc 292 (2004) 1867-1874
29. Kopczyk R.A., Abrams H., Brown A.T., Metheny J.L., and Kaplan A.L. Clinical and microbiological effects of a sanguinaria-containing mouthrinse and dentifrice with and without fluoride during 6 months of use. J. Periodontol 62 (1991) 617-622
30. Ramasamy I. Interited bleeding disorders: disorders of platelet adhesion and aggregation. Crit Rev Oncol Hematol 49 (2004) 1-35
31. Dogne J.M., De Leval X., Hanson J., et al. New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 11 (2004) 1223-1241
32. Colman R.W. Aggregin: a platelet ADP receptor that mediates activation. FASEB J 4 (1990) 1425-1435
33. Maurice P., Legrand C., and Fauvel-Lafeve F. Platelet adhesion and signaling induced by the octapeptide primary binding sequence (KOGEOGPK) from type III collagen. FASEB J 18 (2004) 1339-1347
34. Krotz F., Sohn H.Y., Gloe T., et al. NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100 (2002) 917-924
35. Simmons D.L., Botting R.M., and Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Res 56 (2004) 387-437
36. Tenenbaum H., Dahan M., and Soell M. Effectiveness of a sanguinarine regimen after scaling and root planing. J Periodontol 70 (1999) 307-311
37. Grossman E., Meckel A.H., Isaacs R.L., et al. A clinical comparison of antibacterial mouthrinses: effects of chlorhexidine, phenolics, and sanguinarine on dental plaque and gingivitis. J Periodontol 60 (1989) 435-440
38. Loftin C.D., Tiano H.F., and Langenbach R. Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediator 68-69 (2002) 177-185
39. Rotondo S., De Gaetano G., and Cerletti C. Antiplatelet activity of 2-(6-carboxyhexyl)-3-n-hexylcyclohexylamine (IBI P-05006), a thromboxane receptor antagonist. Eur J Pharmacol 232 (1993) 41-45
40. Hu C.M., Cheng H.W., Cheng Y.W., and Kang J.J. Mechanisms underlying the induction of vasorelaxation in rat thoracic aorta by sanguinarine. Jpn J Pharmacol 85 (2001) 47-53
41. Hu C.M., Cheng H.W., Cheng Y.W., and Kang J.J. Induction of skeletal muscle contracture and calcium release from isolated sarcoplasmic reticulum vesicles by sanguinarine. Br J Pharmacol 130 (2000) 299-306
42. 2+ responses and platelet aggregation by the P2Y12 receptor antagonists AR-C69931MX and clopidogrel is enhanced by prostaglandinEl. Cell Calcium 35 (2004) 39-46
43. Dangelmaier C., Jin J., Smith J.B., and Kunapuli S.P. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 85 (2001) 341-348
44. Daniel J.L., Dangelmaier C., Jin J., Kim Y.B., and Kunapuli S.P. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 82 (1999) 1322-1326
45. + ATPase. Eur J Pharmacol 60 (1979) 373-377
46. 2+ influx in cardiac muscle by snaguinarine: a study on cardiotoxicity of sanguinarine. J Biomed Sci 12 (2005) 399-407